Traduction de «patch is approved for the treatment » (Néerlandais → Français) :

Exelon Patch is approved for the treatment of mild-to-moderate Alzheimer’s disease dementia in more than 75 countries, including more than 20 countries where it is also approved for dementia associated with Parkinson’s disease.
Exelon Patch est autorisé dans plus de 75 pays pour le traitement des formes légère à modérée de la maladie d'Alzheimer et dans plus de vingt pour celui de la démence associée à la maladie de Parkinson.

Exelon Patch is approved for the treatment of mild to moderate Alzheimer’s disease dementia in more than 75 countries, including more than 20 countries where it is also approved for dementia associated with Parkinson’s disease.
Exelon Patch est autorisé dans plus de 75 pays pour le traitement des formes légère à modérée de la maladie d'Alzheimer et dans plus de 20 pour celui de la démence associée à la maladie de Parkinson.

Submission for US approval of a triple combination therapy for hypertension in a single pill containing Tekturna/Rasilez, amlodipine and hydrochlorothiazide as well as Exelon Patch (Alzheimer’s disease) and Tasigna (cancer) for approval in Japan.
Dépôt d’une demande d’homologation aux Etats-Unis pour une trithérapie contre l’hypertension artérielle associant trois médicament dans un seul comprimé contenant Rasilez/Tekturna, amlodipine et hydrochlorothiazide, ainsi qu’au Japon pour Exelon Patch (maladie d’Alzheimer) et Tasigna (cancer).

Reclast/Aclasta, approved for five indications, gained additional US approval in May as the only therapy to prevent postmenopausal osteoporosis with convenient, less-frequent dosing, while European approval was granted in June for treatment of osteoporosis caused by steroid treatment in men and postmenopausal women, an indication already approved in the US.
Autorisé pour cinq indications, Aclasta/Reclast a obtenu en mai des autorisations supplémentaires aux Etats-Unis en tant que seul traitement pratique et peu fréquent destiné à prévenir l’ostéoporose postménopausique. En Europe, l’autorisation a été accordée en juin pour le traitement de l’ostéoporose provoquée par des stéroïdes chez l’homme et la femme postménopausée, indication déjà homologuée aux Etats-Unis.

Our oncology franchise continues to expand its portfolio, as Tasigna (an improved therapy over Glivec) has received recommendation for approval in the EU and approval in Switzerland as a first-line treatment for patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML), a form of blood cancer.
Domaine thérapeutique stratégique, Oncologie continue d’étendre son portefeuille: Tasigna, qui représente une amélioration par rapport à Glivec, a reçu des avis favorables à une homologation par l’UE et a été autorisé en Suisse en tant que traitement de première ligne de la leucémie myéloïde chronique à chromosome Philadelphie positif (LMC Ph+), une forme du cancer du sang.

Gleevec/Glivec, a targeted therapy for certain forms of CML and GIST, was approved in 2009 for use in adjuvant treatment of patients following complete gross resection of GIST and has since received approvals for this indication in more than 55 countries.
Glivec/Gleevec, un traitement ciblé contre certaines formes de LMC et de GIST, a été homologué en 2009 pour son utilisation comme adjuvant dans les résections complètes de GIST et a depuis été autorisé pour cette indication dans plus de 55 pays.

Spontaneous cessation rate: 2.5% OR counselling only: 1.73 Incremental OR NRT gum (relative to counselling only): 1.63 Incremental OR NRT patch (relative to counselling only): 1.79 Incremental OR NRT spray (relative to counselling only): 2.35 Incremental OR NRT inhaler (relative to counselling only): 2.14 Incremental OR bupropion (relative to counselling only): 2.30 % of smokers still under treatment after the first month: 50% (range 40-60% in sensitivity analysis) % of smokers still under treatment after the second month: 20% (range 15-25% in sensitivity analysis) Lifetime relapse probability after one year of abstinence: 35% (range 10-50% in sensitivity analysis) Effect of smoking cessation on mortality derived from the results of the American Cancer Society Prevention Study II. The mortality rate for former smokers was projected by calculating a weighted average of the incremental differentials between mortality rates of neversmokers and smokers, weighted according to the duration of abstinence.
Spontaneous cessation rate: 2.5% OR counselling only: 1.73 Incremental OR NRT gum (relative to counselling only): 1.63 Incremental OR NRT patch (relative to counselling only): 1.79 Incremental OR NRT spray (relative to counselling only): 2.35 Incremental OR NRT inhaler (relative to counselling only): 2.14 Incremental OR Buproprion (relative to counselling only): 2.30 % of smokers still under treatment after the first month: 50% (range 40-60% in sensitivity analysis) % of smokers still under treatment after the second month: 20% (range 15-25% in sensitivity analysis) Lifetime relapse probability after one year of abstinence: 35% (range 10-50% in sensitivity analysis) Effect of smoking cessation on mortality derived from the results of the American Cancer Society Prevention Study II. The mortality rate for former smokers was projected by calculating a weighted average of the incremental differentials between mortality rates of neversmokers and smokers, weighted according to the duration of abstinence.

The FDA approved Tekamlo (aliskiren and amlodipine) tablets, a single-pill combination for the treatment of high blood pressure combining the only approved direct renin inhibitor, Tekturna (aliskiren), with the widely used calcium channel blocker, amlodipine.
traitement de l’hypertension. Il s’agit d'une association de Rasilez/Tekturna (aliskirène), le seul inhibiteur direct de la rénine homologué, avec l’amlodipine, un inhibiteur des canaux calciques largement utilisé.

Treatment (both NRT and bupropion) lasts at least 1 month Retail price of NRT gum: not reported Retail price of NRT patch (3-month course): €354.54 (€, 2001) Retail price of NRT nasal spray (3-months course): €743.02 3% (range 0-5% in sensitivity analysis)
Treatment (both NRT and Buproprion) lasts at least 1 month Retail price of NRT gum: not reported Retail price of NRT patch (3-month course): €354.54 (€, 2001) Retail price of NRT nasal spray (3-months course): €743.02 3% (range 0-5% in sensitivity analysis)